What is an ERBB2 hercep IHC cancer screening test?

The ERBB2 (HER2/neu) IHC cancer screening test is a diagnostic test used to detect the presence of the HER2 protein in breast cancer cells. This test involves using antibodies to stain tissue samples taken during a biopsy or surgery and is used to determine the extent to which HER2 is overexpressed in the cancer cells. This information is important because it can help doctors determine the most effective treatment plan for the patient.

Is the ERBB2 HER2 IHC cancer screening test in accurate?

The ERBB2/HER2 IHC cancer screening test is a widely used diagnostic tool for breast cancer in , India. As with any medical test, accuracy is a critical factor in ensuring proper diagnosis and treatment of patients.

The ERBB2/HER2 IHC test is designed to detect the presence of the HER2 protein in the cells of a patient's breast tissue. This protein is known to play a crucial role in the development and progression of certain types of breast cancer.

In terms of accuracy, the ERBB2/HER2 IHC test has been found to be a highly reliable indicator of HER2 protein expression in breast cancer patients. In fact, it is considered the gold standard for determining HER2 status in breast cancer patients, and is routinely used in clinical practice.

However, it is important to note that accuracy may depend on a variety of factors, including the quality and consistency of the testing procedure, as well as the experience and expertise of the healthcare professionals performing the test.

Therefore, it is crucial for patients to seek out reputable healthcare providers and laboratories when undergoing cancer screening tests such as the ERBB2/HER2 IHC test. Patients should also be aware that false positives and false negatives can occur with any medical test, and should work closely with their healthcare providers to ensure accurate diagnosis and appropriate treatment.

In conclusion, the ERBB2/HER2 IHC cancer screening test is a highly accurate diagnostic tool for breast cancer in , but accuracy is dependent on proper testing procedures and the expertise of healthcare professionals. Patients should prioritize seeking out reputable healthcare providers and laboratories when undergoing cancer screening tests to ensure accurate diagnosis and appropriate treatment. False positives and false negatives can occur with any medical test, so it is important for patients to work closely with their healthcare providers to ensure accurate diagnosis and appropriate treatment. Remember, early detection and accurate diagnosis are crucial for successful treatment and recovery from breast cancer.

How long does it take to get results from the ERBB2 HER2 IHC cancer screening test in ?

The duration of the ERBB2 HER2 IHC cancer screening test may vary depending on the laboratory testing the sample in . However, generally, it takes around 2-3 days to get the test results.

The ERBB2 HER2 IHC cancer screening test is a diagnostic test that is used to detect the presence of HER2 protein in breast cancer cells. The test is performed on a tissue sample obtained through a biopsy or surgical procedure. The sample is then sent to a laboratory for analysis.

The laboratory technicians will process the sample and perform the immunohistochemistry (IHC) test to determine the level of HER2 protein expression in the cancer cells. The results of the ERBB2 HER2 IHC test are reported as a score from 0 to 3+. A score of 0 or 1+ indicates that there is a low level of HER2 protein expression, whereas a score of 3+ indicates a high level of HER2 protein expression.

Once the test is completed, the laboratory will send the results to the healthcare provider who ordered the test. The healthcare provider will then review the results with the patient and discuss the appropriate treatment options.

In conclusion, the ERBB2 HER2 IHC cancer screening test results can be obtained within 2-3 days in . It is important to note that the duration of the test may vary depending on the laboratory and the healthcare provider's availability to review the results with the patient.

What is the cost of the ERBB2 HER2 IHC cancer screening test in ?

The cost of ERBB2 HER2 IHC cancer screening test in can vary depending on several factors such as the laboratory, the method used, and the location. It is important to note that this particular test is usually performed as a part of a broader panel of diagnostic tests and not as a standalone test.

As per our research, the cost of ERBB2 HER2 IHC cancer screening test in typically ranges from Rs. 2,500 to Rs. 5,000. However, it is important to note that this cost can vary depending on the laboratory chosen and the specific requirements of the patient.

It is advisable to consult with a healthcare professional, preferably an oncologist, to determine the best diagnostic plan and the cost of the tests required. They will be able to provide specific guidance on the most appropriate diagnostic tests to be performed and the most cost-effective options available.

Furthermore, it is important to keep in mind that cancer screening tests are crucial for early detection and timely intervention. Therefore, one should not solely base their decision on the cost of the test but should instead prioritize their health and wellbeing.

In conclusion, the cost of ERBB2 HER2 IHC cancer screening test in can vary, and it is recommended to consult with a healthcare professional to determine the most appropriate diagnostic plan and the cost of the tests required. Ultimately, one should prioritize their health and well-being over the cost of the test.

Methodology: Immunohistochemistry

TAT: 3-5 days

Specimen Preparation
Collect - tissue /or cell
Specimen Preparation- formal fix (10 % neutral buffered formalin) and paraffin enter specimen (FFPE specimens square measure needed). shield paraffin block or slides from uncontrolled heat. Transport tissue block or five unstained (3-micron thick sections), charged slides during a tissue transport kit. (Min: a pair of slides). If causing precut slides, don't over heat it.
Storage/Transport Temperature- At temperature or cold. Transport it in cooled instrumentation throughout weather.
Unacceptable conditions- i) Specimens submitted with non-marked/tagged tissue sort square measure rejected.
ii) Depleted specimens aren't tested.
Stability- i) Ambient: Indefinitely;
ii) Refrigerated: Indefinitely;
iii) Frozen: Unacceptable